Iovance Biotherapeutics Inc
IOVA1.750USD
-1.420-44.79%
Fechamento 05/09, 16:00（ET）Cotações atrasadas em 15 min
534.19MValor de mercado
PerdaP/L TTM
Mais detalhes de Iovance Biotherapeutics Inc Empresa
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Informações da empresa
Código da empresaIOVA
Nome da EmpresaIovance Biotherapeutics Inc
Data de listagemJun 20, 2008
Fundado em2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
Número de funcionários838
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço825 Industrial Road
CidadeSAN CARLOS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94070
Telefone16502607120
Sitehttps://www.iovance.com/
Código da empresaIOVA
Data de listagemJun 20, 2008
Fundado em2017
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: dom, 4 de mai
Tempo de atualização: dom, 4 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Estatísticas dos acionistas
Acionista
Proporção
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Tipo
Acionista
Proporção
Investment Advisor
24.77%
Investment Advisor/Hedge Fund
21.77%
Private Equity
13.95%
Hedge Fund
8.74%
Venture Capital
8.50%
Research Firm
3.25%
Bank and Trust
0.70%
Pension Fund
0.54%
Individual Investor
0.31%
Other
17.47%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
658
278.41M
85.05%
-24.34M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
2022Q4
639
197.16M
124.92%
+7.22M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Quogue Capital L.L.C.
28.07M
8.56%
+5.00M
+21.68%
Feb 20, 2024
The Vanguard Group, Inc.
27.48M
8.38%
+210.50K
+0.77%
Dec 31, 2024
MHR Fund Management LLC
24.42M
7.45%
+420.00K
+1.75%
Dec 31, 2024
Perceptive Advisors LLC
22.11M
6.74%
-4.51M
-16.93%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.17M
6.15%
+1.46M
+7.80%
Dec 31, 2024
State Street Global Advisors (US)
12.25M
3.74%
-952.70K
-7.22%
Dec 31, 2024
Hood River Capital Management LLC
8.99M
2.74%
+846.94K
+10.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.56M
2%
-1.97M
-23.08%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.87M
1.79%
+222.43K
+3.94%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
5.83M
1.78%
-26.82K
-0.46%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
1.21%
WisdomTree BioRevolution Fund
0.76%
Virtus LifeSci Biotech Products ETF
0.69%
Range Cancer Immunotherapy ETF
0.6%
SPDR S&P Biotech ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.08%
Strive Small-Cap ETF
0.06%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção1.21%
WisdomTree BioRevolution Fund
Proporção0.76%
Virtus LifeSci Biotech Products ETF
Proporção0.69%
Range Cancer Immunotherapy ETF
Proporção0.6%
SPDR S&P Biotech ETF
Proporção0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.18%
ProShares Ultra Nasdaq Biotechnology
Proporção0.11%
Invesco Nasdaq Biotechnology ETF
Proporção0.11%
iShares Biotechnology ETF
Proporção0.08%
Strive Small-Cap ETF
Proporção0.06%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados